SCHEMBL2655630

SCHEMBL2655630

CCN1Cc2nc3c(-c4c(F)cccc4OC)c(F)ccc3c(N)c2C1=O

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GABRG2 P18507 4/20 0.39
▸ GABRB3 P28472 4/20 0.39
▸ GABRA2 P47869 4/20 0.39
▸ GABRA1 P14867 1/20 0.39
▸ GABRA5 P31644 1/20 0.39
▸ GABRA3 P34903 1/20 0.39
▸ PDE5A O76074 5/20 0.39
▸ RPS6KA2 Q15349 1/20 0.35
▸ PDE6C P51160 1/20 0.34
▸ MAP4K1 Q92918 3/20 0.34
▸ HCRTR1 O43613 1/20 0.32
▸ HCRTR2 O43614 1/20 0.32
▸ HTR2C P28335 2/20 0.32
▸ HTR5A P47898 1/20 0.32
▸ CRHR1 P34998 2/20 0.31
▸ HTR2A P28223 1/20 0.31
▸ HTR2B P41595 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2655372 0.92 GABRG2 (0.40) GABRG2GABRB3GABRA2GABRA1GABRA5
SCHEMBL2661341 0.90 GABRG2 (0.38) GABRG2GABRB3GABRA2GABRA1GABRA5
SCHEMBL4919706 0.89 GABRA1 (0.49) GABRG2GABRB3GABRA2GABRA1GABRA5
SCHEMBL2656331 0.89 PDE5A (0.40) GABRG2GABRB3GABRA2GABRA1GABRA5
SCHEMBL2658326 0.87 GABRG2 (0.37) GABRG2GABRB3GABRA2GABRA1GABRA5
SCHEMBL2655495 0.86 GABRG2 (0.43) GABRG2GABRB3GABRA2PDE5APDE6C
SCHEMBL2660050 0.85 PDE5A (0.39) GABRG2GABRB3GABRA2PDE5APDE6C
SCHEMBL2656086 0.85 PDE5A (0.41) GABRG2GABRB3GABRA2PDE5APDE6C
SCHEMBL2655743 0.84 GABRG2 (0.37) GABRG2GABRB3GABRA2PDE5APDE6C
SCHEMBL2661396 0.84 PDE5A (0.43) GABRG2GABRB3GABRA2GABRA1GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF GABRG2 592/4885GABRB3 332/4885GABRA2 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback